







an Open Access Journal by MDPI

Advances in Breast Cancer Research: From Biology to Pathology

Guest Editors:

Prof. Dr. Reiner Strick

Department of Gynecology, University Hospital Erlangen, Laboratory for Molecular Medicine, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany

Dr. Ramona Erber

Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany

Deadline for manuscript submissions:

closed (30 April 2023)

Message from the Guest Editors

Breast cancer represents histological and molecular tumor subtypes, including luminal, basal, claudin-low, HER2-enriched, and unclassified subtypes stemming from different cellular origins and/or somatic changes, which are essential for the diagnosis and prediction of patient survival and therapy. Understanding the biology of non-neoplastic breast parenchyma as well as breast cancer will lead to better understandings of carcinogenesis and metastases, where both involve essential interaction with the tumor immune microenvironment.

We are pleased to invite you to submit research papers, reviews, communications, etc., for this Special Issue of Cancers, "Advances in Breast Cancer Research: from Biology to Pathology". Cancers encourages authors to publish experimental and theoretical results in as much detail as possible, which also include studies showing meaningful but negative results. We invite high-quality articles including basic, translational, and clinical studies on breast normal and tumor biology and pathology.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us